Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets.

Wimmers F, Schreibelt G, Sköld AE, Figdor CG, De Vries IJ.

Front Immunol. 2014 Apr 11;5:165. doi: 10.3389/fimmu.2014.00165. eCollection 2014. Review.

2.

Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy.

Schreibelt G, Tel J, Sliepen KH, Benitez-Ribas D, Figdor CG, Adema GJ, de Vries IJ.

Cancer Immunol Immunother. 2010 Oct;59(10):1573-82. doi: 10.1007/s00262-010-0833-1. Epub 2010 Mar 5. Review.

PMID:
20204387
3.

Primary Human Blood Dendritic Cells for Cancer Immunotherapy-Tailoring the Immune Response by Dendritic Cell Maturation.

Sittig SP, de Vries IJM, Schreibelt G.

Biomedicines. 2015 Dec 2;3(4):282-303. doi: 10.3390/biomedicines3040282. Review.

5.

The aryl hydrocarbon receptor antagonist StemRegenin 1 promotes human plasmacytoid and myeloid dendritic cell development from CD34+ hematopoietic progenitor cells.

Thordardottir S, Hangalapura BN, Hutten T, Cossu M, Spanholtz J, Schaap N, Radstake TR, van der Voort R, Dolstra H.

Stem Cells Dev. 2014 May 1;23(9):955-67. doi: 10.1089/scd.2013.0521. Epub 2014 Jan 24.

PMID:
24325394
6.

Crosstalk between dendritic cell subsets and implications for dendritic cell-based anticancer immunotherapy.

Bakdash G, Schreurs I, Schreibelt G, Tel J.

Expert Rev Clin Immunol. 2014 Jul;10(7):915-26. doi: 10.1586/1744666X.2014.912561. Epub 2014 Apr 23. Review.

PMID:
24758519
7.

RNA-based immunotherapy of cancer: role and therapeutic implications of dendritic cells.

Tyagi RK, Mangal S, Garg N, Sharma PK.

Expert Rev Anticancer Ther. 2009 Jan;9(1):97-114. doi: 10.1586/14737140.9.1.97. Review. Retraction in: Expert Rev Anticancer Ther. 2011 Nov;11(11):1778.

PMID:
19105710
8.

Role of conventional treatments on circulating and monocyte-derived dendritic cells in colorectal cancer.

Bellik L, Gerlini G, Parenti A, Ledda F, Pimpinelli N, Neri B, Pantalone D.

Clin Immunol. 2006 Oct;121(1):74-80. Epub 2006 Aug 17.

PMID:
16914380
9.

Genetically modified dendritic cells in cancer therapy: implications for transfusion medicine.

Foley R, Tozer R, Wan Y.

Transfus Med Rev. 2001 Oct;15(4):292-304. Review.

PMID:
11668436
10.

IL-4 blocks TH1-polarizing/inflammatory cytokine gene expression during monocyte-derived dendritic cell differentiation through histone hypoacetylation.

López-Bravo M, Minguito de la Escalera M, Domínguez PM, González-Cintado L, del Fresno C, Martín P, Martínez del Hoyo G, Ardavín C.

J Allergy Clin Immunol. 2013 Dec;132(6):1409-19. doi: 10.1016/j.jaci.2013.08.039. Epub 2013 Oct 17.

PMID:
24139608
11.
12.

Human dendritic cell subsets display distinct interactions with the pathogenic mould Aspergillus fumigatus.

Lother J, Breitschopf T, Krappmann S, Morton CO, Bouzani M, Kurzai O, Gunzer M, Hasenberg M, Einsele H, Loeffler J.

Int J Med Microbiol. 2014 Nov;304(8):1160-8. doi: 10.1016/j.ijmm.2014.08.009. Epub 2014 Aug 18.

PMID:
25200858
13.

Dendritic cell gene therapy.

Onaitis M, Kalady MF, Pruitt S, Tyler DS.

Surg Oncol Clin N Am. 2002 Jul;11(3):645-60. Review.

PMID:
12487060
14.

Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.

Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J.

J Immunother. 2006 Sep-Oct;29(5):545-57.

PMID:
16971810
15.

Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomes.

Cornwall SM, Wikstrom M, Musk AW, Alvarez J, Nowak AK, Nelson DJ.

Oncoimmunology. 2015 Aug 31;5(2):e1082028. eCollection 2016 Feb.

16.

Dab2, a negative regulator of DC immunogenicity, is an attractive molecular target for DC-based immunotherapy.

Ahmed MS, Byeon SE, Jeong Y, Miah MA, Salahuddin M, Lee Y, Park SS, Bae YS.

Oncoimmunology. 2015 Feb 3;4(1):e984550. eCollection 2015 Jan.

17.

Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen.

Smithers M, O'Connell K, MacFadyen S, Chambers M, Greenwood K, Boyce A, Abdul-Jabbar I, Barker K, Grimmett K, Walpole E, Thomas R.

Cancer Immunol Immunother. 2003 Jan;52(1):41-52. Epub 2002 Nov 13.

PMID:
12536239
18.

Dendritic cell vaccines for cancer immunotherapy.

Timmerman JM, Levy R.

Annu Rev Med. 1999;50:507-29. Review.

PMID:
10073291
19.

Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition.

Tel J, Koornstra R, de Haas N, van Deutekom V, Westdorp H, Boudewijns S, van Erp N, Di Blasio S, Gerritsen W, Figdor CG, de Vries IJ, Hato SV.

J Transl Med. 2016 Apr 14;14:88. doi: 10.1186/s12967-016-0844-6.

20.

Naturally circulating dendritic cells to vaccinate cancer patients.

Bol KF, Tel J, de Vries IJ, Figdor CG.

Oncoimmunology. 2013 Mar 1;2(3):e23431.

Supplemental Content

Support Center